Infex agrees collaboration with Asian clinical trials network, ADVANCE-ID
Memorandum of Understanding signed to investigate hospital-acquired drug-resistant infections in Asia
Infex signs exclusive license agreement with Venus Remedies Ltd to advance MET-X through clinical development and commercialisation in India
Infex Therapeutics, a leading anti-infectives specialist, announces that it has signed an exclusive license agreement for the Indian market…
Infex and Justus-Liebig-University Giessen awarded £1 million grant from PACE
Grant to develop first-in-class antimicrobial drug targeting multi-drug-resistant bacteria
First NCFB patient dosed in Phase IIa study of RESP-X
Potential first-in-class anti-virulence antibody drug to reduce the frequency of debilitating exacerbations in respiratory patients with…
Infex invites you to Alderley Park’s 10th Anniversary SciTech Extravaganza
Come and join us in Glasshouse at Alderley Park for an interactive and inspiring day of science and technology fun, in collaboration with…
Infex to present RESP-X Phase I data at ERS Congress
RESP-X is a potential blockbuster anti-virulence antibody drug to reduce the frequency of debilitating exacerbations in respiratory…
Infex strengthens its senior leadership team
Appointment of Director of Clinical Programmes and changes to senior management team
Infex webinar – broader pipeline and growth strategy
On 9th May 2024, Infex Therapeutics held a live webinar, to update on the company's broader pipeline and growth strategy.
Infex welcomes the UK government’s new five-year plan to combat antimicrobial resistance
Infex Therapeutics, a leading anti-infectives specialist, welcomes the UK government’s new five-year national action plan to help combat…
